Scarica l'app Stockscreener
2.56
4.49%
0.11
Dopo l'orario di chiusura:
2.43
-0.13
-5.08%
Precedente Chiudi:
$2.45
Aprire:
$2.4
Volume 24 ore:
29,497
Relative Volume:
0.02
Capitalizzazione di mercato:
$20.21M
Reddito:
$34.75M
Utile/perdita netta:
$-24.76M
Rapporto P/E:
-0.2133
EPS:
-12
Flusso di cassa netto:
$-50.91M
1 W Prestazione:
+4.07%
1M Prestazione:
-5.88%
6M Prestazione:
-75.46%
1 anno Prestazione:
-91.87%
Intervallo 1D:
$2.40
$2.59
Intervallo di 1 settimana:
$2.40
$2.59
Portata 52W:
$2.15
$33.75
Allurion Technologies Inc Stock (ALUR) Company Profile
Nome
Allurion Technologies Inc
Settore
Industria
Telefono
508-647-4000
Indirizzo
11 HURON DR STE 200, NATICK
Confronta ALUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.56 | 20.21M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-02 | Iniziato | TD Cowen | Buy |
| 2024-09-06 | Iniziato | ROTH MKM | Buy |
| 2024-02-09 | Iniziato | Jefferies | Buy |
Allurion Technologies Inc Borsa (ALUR) Ultime notizie
Major Weight Loss Breakthrough: 20,000 Patient Study Reveals Muscle-Preserving Success of Allurion Program - Stock Titan
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS - New Castle News
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Down 42.4% in May - Defense World
(ALUR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Allurion Technologies (NYSE:ALUR) Trading 2.1% Higher – Time to Buy? - Defense World
Allurion at Jefferies Conference: Strategic US Market Entry By Investing.com - Investing.com South Africa
Allurion at Jefferies Conference: Strategic US Market Entry - Investing.com Australia
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - The Globe and Mail
Allurion to Present at Jefferies Global Healthcare Conference - BioSpace
When the Price of (ALUR) Talks, People Listen - news.stocktradersdaily.com
ALURALLURION TECHNOLOGIES INC Latest Stock News & Market Updates - Stock Titan
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results - MSN
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program - BioSpace
Allurion Weight Loss Program Builds Muscle Mass 6.6%, Cuts Fat 11% in Clinical Study | ALUR Stock News - Stock Titan
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
4 Medical Product Stocks to Watch From a Challenging Industry - Yahoo Finance
Trend Tracker for (ALUR) - news.stocktradersdaily.com
Research Analysts Offer Predictions for ALUR FY2025 Earnings - Defense World
Yale University's Strategic Exit from Allurion Technologies Inc: A 13F Filing Insight - GuruFocus
Allurion Technologies Earnings Call: Transition and Growth - TipRanks
Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025 - MSN
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates - MSN
Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Allurion Technologies Reports Q1 2025 Financial Results - TipRanks
Allurion Technologies (ALUR) Unveils Promising Obesity Treatment Results | ALUR Stock News - GuruFocus
Allurion Technologies (ALUR) Q1 2025 Results Highlight Revenue a - GuruFocus
Transcript : Allurion Technologies Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
What To Expect From Allurion Technologies Inc (ALUR) Q1 2025 Ear - GuruFocus
Allurion To File Final Module Of Weight Loss Balloon To FDA For Approval Next Month - Nasdaq
Allurion Technologies (ALUR) Surges Over 50% Following Data Pres - GuruFocus
Earnings call transcript: Allurion Technologies Q1 2025 sees revenue drop, stock surges - Investing.com
Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript - MSN
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Prom - GuruFocus
Allurion Technologies Q1 2025 Financial Results - TradingView
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Promising Year | ALUR Stock News - GuruFocus
Allurion Technologies reports Q1 EPS 20c vs. ($2.78) last year - TipRanks
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
After-Market Rally For Allurion (ALUR) As New Data Sparks Investor Optimism - Stocks Telegraph
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss - 01net
Allurion reports weight loss breakthrough at obesity congress - Investing.com Australia
Allurion reports weight loss breakthrough at obesity congress By Investing.com - Investing.com Nigeria
New Clinical Data: Allurion's Swallowable Balloon Supercharges GLP-1 Weight Loss Results, Preserves Muscle - Stock Titan
Allurion Technologies Inc Azioni (ALUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Allurion Technologies Inc Azioni (ALUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gaur Shantanu | Chief Executive Officer |
Mar 28 '25 |
Buy |
3.35 |
8,000 |
26,800 |
8,000 |
0.54%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):